Breast cancer molecular subtypes and their clinicopathological characteristics amongst patients at the Aga Khan university hospital (Nairobi)

Annals of African Surgery

Volumn 5, Issue , 2010, Pages 19-24

  Gakinya, Samuel M ^a   Sayed, S ^a   Chauhan, R ^a   Sayed, P ^a  

^a AGA KHAN UNIVERSITY   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER MOLECULAR SUBTYPE; CANCER GRADING; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CAUCASIAN; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSE; TREATMENT RESPONSE;

EID: 79960434991     PISSN: 19999674     EISSN: 25230816     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bjerregaard B, Kungu A. Breast cancer in Kenya. A histopathologic and epidemiologic study. East Afr Med J 1992. 69:62.
2. G.Z Mutuma, A.R Korir. Nairobi cancer registry 2000-2002, Kenya medical research institute. Cancer incidence report. October2006.
3. Rosai J. Rosai and Ackerman's surgical pathology 9th ed. Elselvier Inc., St. Louis, MD, 2004.
4. Kumar V, Abbas A, Fausto N. Robbins and Cotran, Pathologic basis of disease. 7th edition W.B Saunders co. 2004.
5. Vincent T. Devita. Cancer principles and practice of oncology. 7th edition, Lippincot Williams and wilkins 2005.
6. Perou CM, Jeffrey SS, van de Rijn M. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA. 1999;96:9:212-7.
7. Sotiriou C, Neo SY, McShane LM. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393-8.
8. Van de Rijn M, Perou CM, Tibshirani R. Expression of cy tokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Amer J Path 2002;161:1991-6.
9. Banerjee A. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J of Clin Path 2006;59:729-735
10. Mervi Laakso. Basoluminal Carcinoma: A new biologically and prognostically distinct entity between basal and luminal breast cancer clinical cancer research. 2006;12; 4185-4191.
11. Jones C, Ford E, Gillett C. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clinical Cancer Research. 2004;10:5988-97.
12. Lisa A. Carey, Perou CM, Livasy CA et al. Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-2502.
13. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J of Cancer. 2005; 116:340-50.
14. Lajos Pusztai, Chafika Mazouni. Molecular Classification of Breast Cancer: Limitations and potential The Oncologist. 2006; 11:868-877.
15. Taylor-Papadimitriou, J. Keratin expression in human mammary epithelial cells cultured from normal and malignant tissue: relation to in vivo phenotypes and influence of medium. Journal of Cell Science. 1989; 94:403-413.
16. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J of Path 2004; 203:661-71.
17. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98:10869-74.
18. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J of the Natl Cancer Institute. 2006;98: 262-272.
19. Perou CM, Sorlie T, Eisen MB, van de Rijn et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752.
20. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23.
21. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
22. Mi-Jung Kim MD, PhD et.al, Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Human pathology. 2006;(37)9.
23. Zarcone M., Rosalba Amodio, et.al. Application of a New classification to a breast tumor series from a population-based cancer registry. Ann. N.Y. Acad. Sci. 2009; 1155: 222-226.
24. Nyagol J., Nyongo A., Byakika B., Muchiri L. et.al. Routine assessment of hormonal receptor and Her-2 status underscores the need for more therapeutic targets in Kenyan women with Breast cancer. Analytical and quantitative cytology and Histology. 2006;28:2.
25. Bird P.A, Hill A.G, Houssami N. Poor hormone receptor expression in East African Breast cancer: evidence of biologically different disease? Ann of Surg Oncol.2008; 15(7):1983-1988.
26. Nalwoga H, Arnes JB, Wabinga H, Akslen LA. Frequency of the basal-like phenotype in African breast cancer. APMIS. 2007;115:1391-9.